
OVERVIEW
We are developing therapeutics to target the most common oral cancer using a simple local delivery system that combines both diagnostic and therapeutic capabilities.
This approach enables early identification of oral squamous cell carcinoma and instant treatment by inducing apoptosis (natural cell death) of the selected cells and tissues with minimal damage to healthy cells.
Our therapeutics are based on the development of their patented fluorescent imaging and probe technologies.
We are offering these probes for research imaging applications through Merck and for research use as therapeutics which enable cell imaging, detection, tracking and tagging of bioactive molecules, with these tags imaged using fluorescence and/or Raman spectroscopy.
The probes are drug-like molecules, smaller than other commercially available similar products, meaning they bypass many traditional problems associated with other fluorescent bioprobes. They pass freely into cells with minimal disruption of cell activity prior to light activation, fundamentally changing the way in which these such phototherapeutic compounds can be delivered to patients.
NEWS & EVENTS
Latest News


CEO Sam Whitehouse showcases at BioSeed Express
